Doctor-reviewed adult vaccine plans and workplace camps for Indians over 40
TL;DR Jabplan turns adult vaccination into a plan people actually finish. A short health questionnaire becomes a doctor-reviewed list of due vaccines, given at workplace and housing-society camps or partner clinics, with reminders for second doses. Employers and resident associations pay for the camps, and individuals pay for the vaccines.
Almost no Indian adult gets vaccinated. In the national LASI survey of 64,714 people aged 45 and over, 1.5% had ever had a flu shot and 0.6% a pneumococcal vaccine[2]. Newer NSS data from 2025 put coverage at 0.43% for people over 50, and about 95% of all adult doses were tetanus boosters given in pregnancy[3].
There's no national adult programme, so adult vaccination is left to private clinics and to people's memory[3]. Doctors rarely bring it up in a short consult. And the people who do want a shingles or pneumonia shot often don't know which ones they need, where to get them or when the second dose is due.
The regulatory bit first - Jabplan does preventive-care coordination. A registered doctor recommends and a licensed clinic, doctor or nurse administers. Jabplan does not diagnose or treat illness.
The seed idea was personalised "immunity exposure plans", and I reframed it. Deliberately exposing people to germs is only allowed inside controlled human-infection studies with ethics approval and strict criteria[1], which no consumer service can offer. Vaccines are the tested way to build immunity ahead of illness, and adults are where India's gap is widest.
A user answers ten questions on age, conditions like diabetes or heart disease, pregnancy plans, travel and past vaccines. A doctor checks the answers against published adult schedules and signs off a plan, say flu yearly, pneumococcal once and shingles twice after 50. Jabplan then books the doses at an office camp, a society camp or a partner clinic, keeps a digital card and chases the second dose. Employers get an aggregate dashboard and never see anyone's health answers.
Employees and residents are the users. The individual usually pays for the vaccine at real retail prices - a 2025–26 quadrivalent flu shot lists at ₹2,688[6] and a dose of the shingles vaccine at ₹10,999, with two doses needed[7][5]. Employers and resident welfare associations pay for the camp and the planning, which I estimate at ₹150–400 per enrolled person. Some employers will also chip in for flu shots, the same way they already do for annual health checks.
The data is fresh and stark. ORF's July 2026 analysis of the NSS round is the first national look at adult vaccination by age and income[3]. Kerala's 2026–27 budget set aside ₹50 Cr for pneumococcal vaccination of poorer people over 60, the first state budget line of its kind[4]. Hospital chains are moving too, and one Bengaluru chain launched a life-course vaccination programme in March 2026[9].
Nobody publishes what Indians spend on adult vaccines. The NSS asked about cost but the published analysis doesn't report it[3].
What is firm is the pool. GSK counts about 26 crore Indians over 50[5], and NSS found adult vaccine coverage of just 0.43% in that age group[3]. Most of the flu, pneumococcal and shingles doses that do get given come from private providers[3], so a paying channel exists.
One Pune non-profit runs corporate drives for flu, pneumonia and typhoid next to its child programmes[8]. One hospital chain sells a life-stage vaccination programme through its own hospitals[9]. Both show demand, but each one is tied to a single channel.
The gap is a neutral planner that follows each adult across the full schedule and not just one camp or one hospital's patients.
| Difficulty | Moderate (37/100) |
| Starting capital | ₹42–86 L |
| Time to launch | 3–5 months |
The technology is light. The hard parts are cold chain and clinical safety at camps, which need a doctor on call and an anaphylaxis kit at every site. Selling into HR budgets is slow, and people tend to drop off after the first dose unless the reminders keep coming and the second-dose camp is easy to get to.
Jabplan itself needs no drug licence if partners hold the stock, but every dose has to go through licensed hands.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI decide who gets a vaccine. A registered doctor reviews every plan, and contraindications are a clinical call.
Want to work out the AI layer for Jabplan? Talk to Yash →
Here's what can go south -
I like this for a founder with corporate-health or clinic operations experience and a doctor partner. If you're hoping to build an "immunity" consumer app then it's a poor fit.
First prove that 25% of employees offered a plan at one company actually get at least one paid vaccine within 60 days.
My estimate is ₹42–86 L to launch, covering doctors, camp kits, the planning software and HR sales. Individuals pay for the vaccines themselves. The kit breaks it down line by line.
Anyone stocking or selling vaccines needs a drug licence, and a doctor or nurse must give each dose. Working through licensed partner clinics keeps that clean.
Yes. Adult coverage is low in many places, but schedules and pharmacy rules differ, so check with your own regulator first.
The free Jabplan validation kit has the line-by-line capital breakdown, the effort scoring, the vaccine handling and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for HR heads and employees, and 5 assumptions to test. Download the kit →
Thinking about building Jabplan or something close to it? The make-or-break work is turning employer interest into adults who complete their doses, and that's a problem I enjoy working on. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.